Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

BACKGROUND: As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Cardiac safety for trabectedin monotherapy (T) for STS or in c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Jones, Robin L., Herzog, Thomas J., Patel, Shreyaskumar R., von Mehren, Margaret, Schuetze, Scott M., Van Tine, Brian A., Coleman, Robert L., Knoblauch, Roland, Triantos, Spyros, Hu, Peter, Shalaby, Waleed, McGowan, Tracy, Monk, Bradley J., Demetri, George D.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8178483/
https://ncbi.nlm.nih.gov/pubmed/33960681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3903
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars